-
EP3360575
European procedure
Extract from the Register of European Patents
EP About this file: EP3360575
| EP3360575 - TRANSDERMAL PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE AGENTS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 23.02.2024 Database last updated on 26.04.2025 | |
| Former | The patent has been granted Status updated on 17.03.2023 | ||
| Former | Grant of patent is intended Status updated on 15.11.2022 | ||
| Former | Examination is in progress Status updated on 26.03.2021 | ||
| Former | Grant of patent is intended Status updated on 16.11.2020 | ||
| Former | Examination is in progress Status updated on 17.12.2019 | ||
| Former | Request for examination was made Status updated on 13.07.2018 | Most recent event Tooltip | 23.02.2024 | No opposition filed within time limit | published on 27.03.2024 [2024/13] | Applicant(s) | For all designated states Besins Healthcare Luxembourg SARL 2-8 rue Julien Vesque 2668 Luxembourg / LU | [2018/33] | Inventor(s) | 01 /
MASINI-ETEVE, Valérie 4 rue Pierre Loti 92340 Bourg La Reine / FR | 02 /
CANET, Denis c/o Besins Healthcare SA Avenue Louise 287 1050 Bruxelles / BE | [2018/33] | Representative(s) | Nederlandsch Octrooibureau P.O. Box 29720 2502 LS The Hague / NL | [2018/33] | Application number, filing date | 18163659.8 | 27.10.2010 | [2018/33] | Priority number, date | US200925524109P | 27.10.2009 Original published format: US 25524109 P | EP20090178762 | 10.12.2009 Original published format: EP 09178762 | [2018/33] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3360575 | Date: | 15.08.2018 | Language: | EN | [2018/33] | Type: | B1 Patent specification | No.: | EP3360575 | Date: | 19.04.2023 | Language: | EN | [2023/16] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 05.06.2018 | Classification | IPC: | A61K47/10, A61K47/12, A61K47/14, A61K9/06, A61K9/08, A61K31/565, A61K31/568, A61K31/57, A61K31/56, A61K31/566, A61K31/573, A61K9/00, A61P5/00, A61P43/00 | [2020/48] | CPC: |
A61K31/56 (EP,RU,US);
A61K31/565 (EP,RU,US);
A61K31/566 (EP,RU,US);
A61K31/568 (EP,RU,US);
A61K31/57 (EP,RU,US);
A61K31/573 (EP,RU,US);
A61K47/10 (EP,RU,US);
A61K47/12 (EP,RU,US);
A61K47/14 (EP,RU,US);
A61K9/0014 (EP,RU,US);
A61K9/06 (EP,RU,US);
A61P43/00 (EP);
A61P5/00 (EP)
(-)
|
| Former IPC [2018/33] | A61K47/10, A61K47/12, A61K47/14, A61K9/06, A61K9/08, A61K31/565, A61K31/568, A61K31/57, A61K31/56, A61K31/566, A61K31/573 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/33] | Title | German: | TRANSDERMALE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT WIRKSTOFFEN | [2018/33] | English: | TRANSDERMAL PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE AGENTS | [2018/33] | French: | COMPOSITIONS PHARMACEUTIQUES TRANSDERMIQUES COMPRENANT DES PRINCIPES ACTIFS | [2018/33] | Examination procedure | 23.03.2018 | Examination requested [2018/33] | 23.03.2018 | Date on which the examining division has become responsible | 12.02.2019 | Amendment by applicant (claims and/or description) | 20.12.2019 | Despatch of a communication from the examining division (Time limit: M04) | 09.04.2020 | Reply to a communication from the examining division | 17.11.2020 | Communication of intention to grant the patent | 25.03.2021 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 06.05.2021 | Despatch of a communication from the examining division (Time limit: M02) | 14.07.2021 | Reply to a communication from the examining division | 16.11.2022 | Communication of intention to grant the patent | 09.03.2023 | Fee for grant paid | 09.03.2023 | Fee for publishing/printing paid | 09.03.2023 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP10768983.8 / EP2493508 | Opposition(s) | 22.01.2024 | No opposition filed within time limit [2024/13] | Fees paid | Renewal fee | 23.03.2018 | Renewal fee patent year 03 | 23.03.2018 | Renewal fee patent year 04 | 23.03.2018 | Renewal fee patent year 05 | 23.03.2018 | Renewal fee patent year 06 | 23.03.2018 | Renewal fee patent year 07 | 23.03.2018 | Renewal fee patent year 08 | 15.10.2018 | Renewal fee patent year 09 | 31.10.2019 | Renewal fee patent year 10 | 30.10.2020 | Renewal fee patent year 11 | 21.10.2021 | Renewal fee patent year 12 | 27.10.2022 | Renewal fee patent year 13 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 19.04.2023 | [2024/12] | Documents cited: | Search | [A]GB880276 (UPJOHN CO); | [I]US5232703 (BLANK IZHAK [IL]); | [I]US2004175416 (TARAVELLA BRIGITTE [FR], et al); | [I]WO2004091631 (UNIMED PHARMACEUTICALS INC [US], et al); | [I]WO2006040196 (BESINS INT LAB [FR], et al); | [A]US2006239929 (DOW GORDON J [US], et al); | [I]US2007082039 (JONES GERALD S JR [US], et al); |